Related Experiment Videos

Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer

I Vucenik1, G Y Yang, A M Shamsuddin

  • 1Department of Medical and Research Technology, University of Maryland School of Medicine, Baltimore 21201-1192, USA.

Carcinogenesis
|May 1, 1995
PubMed

Insights

Inositol hexaphosphate (InsP6) and inositol (Ins) significantly reduced mammary tumors in a rat model. The combination of InsP6 and Ins showed the best results, with no observed toxicity, indicating potential for cancer prevention and treatment.

Area of Science:

  • Oncology
  • Nutritional Biochemistry
  • Carcinogenesis Research

Background:

  • Inositol hexaphosphate (InsP6) and inositol (Ins) are naturally occurring compounds with demonstrated anti-cancer properties.
  • Previous studies suggest these compounds possess anti-cell proliferative actions in various carcinogenesis models.

Purpose of the Study:

  • To investigate the chemopreventive and therapeutic potential of InsP6 and Ins in a DMBA-induced rat mammary tumor model.
  • To evaluate the efficacy of individual and combined InsP6 and Ins treatments on mammary carcinoma development.

Main Methods:

  • Female Sprague-Dawley rats were administered DMBA to induce mammary tumors.
  • Rats received supplemented drinking water with 15 mM InsP6, 15 mM Ins, or a combination of both, starting two weeks prior to DMBA induction.
  • Tumor incidence, number, multiplicity, and burden were assessed over 45 weeks. Toxicity was evaluated through body weight, serum, and bone mineral levels.

Main Results:

  • All treatment groups (InsP6, Ins, InsP6 + Ins) showed a significant reduction in tumor incidence (P < 0.05).
  • Tumor number, multiplicity, and burden were significantly decreased by InsP6 and Ins treatments.
  • The combination of InsP6 + Ins yielded the most favorable outcomes.
  • No significant toxicity was observed in any treatment group, even with long-term administration.

Conclusions:

  • InsP6 and Ins, individually and in combination, effectively inhibit experimental mammary carcinoma in rats.
  • The combination of InsP6 and Ins demonstrated superior efficacy without adverse effects.
  • These findings highlight the significant potential of InsP6 and Ins as chemopreventive and adjuvant therapeutic agents for mammary cancer.

Related Concept Videos